There were 694 press releases posted in the last 24 hours and 155,061 in the last 365 days.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm

/EIN News/ -- IRVINE, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Depomed, Inc. (“Depomed” or the “Company”) (Nasdaq:DEPO). Investors who purchased or otherwise acquired Depomed shares between February 26, 2015 and August 7, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 17, 2017 lead plaintiff motion deadline.

If you purchased Depomed shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 7, 2017, Depomed announced that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.” When this news reached the public, shares of Depomed declined in value, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com 

Primary Logo

Distribution channels: Consumer Goods, Law